Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system

Biochemical Pharmacology

Volumn 85, Issue 6, 2013, Pages 745-752

  Amaral, Joana Dias ^a   Herrera, Federico ^b   Rodrigues, Pedro Miguel ^a   Dionísio, Pedro Antunes ^a   Outeiro, Tiago Fleming ^b,c,d   Rodrigues, Cecília Maria Pereira ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

BiFC assay; Cancer; Drug discovery; HCT116 cells; p53 Mdm2 interaction

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PUMA PROTEIN;

ARTICLE; BIMOLECULAR FLUORESCENCE COMPLEMENTATION ANALYSIS; CARCINOMA CELL; CELL DEATH; COLORECTAL CARCINOMA; COMPLEX FORMATION; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; MAMMAL CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN INTERACTION; TRANSACTIVATION;

BASE SEQUENCE; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; FLUORESCENCE; HUMANS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874114339     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.12.009     Document Type: Article

References (47)

1. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
2. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323 331 (Pubitemid 27131374)
3. K.H. Vousden, and D.P. Lane p53 in health and disease Nat Rev Mol Cell Biol 8 2007 275 283 (Pubitemid 46474662)
4. M.M. Maslon, and T.R. Hupp Drug discovery and mutant p53 Trends Cell Biol 20 2010 542 555
5. D.A. Freedman, L. Wu, and A.J. Levine Functions of the MDM2 oncoprotein Cell Mol Life Sci 55 1999 96 107 (Pubitemid 29077858)
6. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
7. S. Fang, J.P. Jensen, R.L. Ludwig, K.H. Vousden, and A.M. Weissman Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 J Biol Chem 275 2000 8945 8951 (Pubitemid 30180252)
8. R.K. Geyer, Z.K. Yu, and C.G. Maki The MDM2 RING-finger domain is required to promote p53 nuclear export Nat Cell Biol 2 2000 569 573
9. P. Chene Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface Mol Cancer Res 2 2004 20 28 (Pubitemid 38167104)
10. L. Weber Patented inhibitors of p53-Mdm2 interaction (2006-2008) Expert Opin Ther Pat 20 2010 179 191
11. J. Phan, Z. Li, A. Kasprzak, B. Li, S. Sebti, and W. Guida Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX J Biol Chem 285 2010 2174 2183
12. P. Secchiero, R. Bosco, C. Celeghini, and G. Zauli Recent advances in the therapeutic perspectives of Nutlin-3 Curr Pharm Des 17 2011 569 577
13. G.M. Popowicz, A. Domling, and T.A. Holak The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious Angew Chem Int Ed Engl 50 2011 2680 2688
14. First Clinical Trial Looks At RG7112 As A Way To Disable MDM2 In Leukemia. Medical News Today. MediLexicon, Intl., 9 Dec. 2010. Web. 29 Dec. 2012 in < http://www.medicalnewstoday.com/releases/210729.php >.
15. J. Xu, J. Reumers, J.R. Couceiro, F. De Smet, R. Gallardo, and S. Rudyak Gain of function of mutant p53 by coaggregation with multiple tumor suppressors Nat Chem Biol 7 2011 285 295
16. A.P. Ano Bom, L.P. Rangel, D.C. Costa, G.A. de Oliveira, D. Sanches, and C.A. Braga Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer J Biol Chem 287 2012 28152 28162
17. F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, and J.P. Brown Requirement for p53 and p21 to sustain G2 arrest after DNA damage Science 282 1998 1497 1501 (Pubitemid 28538613)
18. T. Unger, M.M. Nau, S. Segal, and J.D. Minna p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer EMBO J 11 1992 1383 1390
19. S. Solá, R.E. Castro, B.T. Kren, C.J. Steer, and C.M. Rodrigues Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes Biochemistry 43 2004 8429 8438 (Pubitemid 38902521)
20. T. Nagai, K. Ibata, E.S. Park, M. Kubota, K. Mikoshiba, and A. Miyawaki A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications Nat Biotechnol 20 2002 87 90 (Pubitemid 34044921)
21. H. Tidow, R. Melero, E. Mylonas, S.M. Freund, J.G. Grossmann, and J.M. Carazo Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex Proc Natl Acad Sci USA 104 2007 12324 12329 (Pubitemid 47206136)
22. Q. Li, R.R. Falsey, S. Gaitonde, V. Sotello, K. Kislin, and J.D. Martinez Genetic analysis of p53 nuclear importation Oncogene 26 2007 7885 7893 (Pubitemid 350261791)
23. T.J. Magliery, C.G. Wilson, W. Pan, D. Mishler, I. Ghosh, and A.D. Hamilton Detecting protein-protein interactions with a green fluorescent protein fragment reassembly trap: scope and mechanism J Am Chem Soc 127 2005 146 157 (Pubitemid 40094379)
24. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848 (Pubitemid 38174664)
25. C.J.A. Ribeiro, S.P. Kumar, R. Moreira, and M.M. Santos Efficient synthesis of spiroisoxazoline oxindoles Tetrahedron Lett 53 2012 281 284
26. T. Miyashita, and J.C. Reed Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 80 1995 293 299
27. E. Oda, R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, and T. Yamashita Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis Science 288 2000 1053 1058 (Pubitemid 30324238)
28. K. Nakano, and K.H. Vousden PUMA. a novel proapoptotic gene, is induced by p53 Mol Cell 7 2001 683 694 (Pubitemid 32706359)
29. M.D. Kaeser, and R.D. Iggo Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo Proc Natl Acad Sci USA 99 2002 95 100 (Pubitemid 34060322)
30. J. Yu, Z. Wang, K.W. Kinzler, B. Vogelstein, and L. Zhang PUMA mediates the apoptotic response to p53 in colorectal cancer cells Proc Natl Acad Sci USA 100 2003 1931 1936 (Pubitemid 36254551)
31. Q. Zhang, and H. Lu Nutlin's two roads toward apoptosis Cancer Biol Ther 10 2010 579 581
32. J.D. Amaral, R.E. Castro, C.J. Steer, and C.M. Rodrigues p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis Trends Mol Med 15 2009 531 541
33. W. Du, J. Wu, E.M. Walsh, Y. Zhang, C.Y. Chen, and Z.X. Xiao Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3 J Biol Chem 284 2009 26315 26321
34. C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, and H. Hilton Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc Natl Acad Sci USA 103 2006 1888 1893 (Pubitemid 43228788)
35. A. Kunkele, K. De Preter, L. Heukamp, T. Thor, K.W. Pajtler, and W. Hartmann Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas Neuro Oncol 14 2012 859 869
36. S.W. Michnick, P.H. Ear, E.N. Manderson, I. Remy, and E. Stefan Universal strategies in research and drug discovery based on protein-fragment complementation assays Nat Rev Drug Discov 6 2007 569 582 (Pubitemid 47019445)
37. T.K. Kerppola Visualization of molecular interactions by fluorescence complementation Nat Rev Mol Cell Biol 7 2006 449 456 (Pubitemid 44050098)
38. A. Mazars, and R. Fahraeus Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells Biotechnol J 5 2010 377 384
39. P. Colas High-throughput screening assays to discover small-molecule inhibitors of protein interactions Curr Drug Discov Technol 5 2008 190 199
40. F. Herrera, S. Goncalves, and T.F. Outeiro Imaging protein oligomerization in neurodegeneration using bimolecular fluorescence complementation Methods Enzymol 506 2012 157 174
41. C. Gehl, R. Waadt, J. Kudla, R.R. Mendel, and R. Hansch New GATEWAY vectors for high throughput analyses of protein-protein interactions by bimolecular fluorescence complementation Mol Plant 2 2009 1051 1058
42. S.A. Goncalves, J.E. Matos, and T.F. Outeiro Zooming into protein oligomerization in neurodegeneration using BiFC Trends Biochem Sci 35 2010 643 651
43. M.R. Muller, and A. Rao NFAT, immunity and cancer: a transcription factor comes of age Nat Rev Immunol 10 2010 645 656
44. M. Mancini, and A. Toker NFAT proteins: emerging roles in cancer progression Nat Rev Cancer 9 2009 810 820
45. X. Zhang, Z. Zhang, J. Cheng, M. Li, W. Wang, and W. Xu Transcription factor NFAT1 activates the mdm2 oncogene independent of p53 J Biol Chem 287 2012 30468 30476
46. S.R. Volate, B.T. Kawasaki, E.M. Hurt, J.A. Milner, Y.S. Kim, and J. White Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells Mol Cancer Ther 9 2010 461 470
47. S. Shangary, D. Qin, D. McEachern, M. Liu, R.S. Miller, and S. Qiu Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proc Natl Acad Sci USA 105 2008 3933 3938 (Pubitemid 351723502)